Login
$GRCE
$1.75 -$0.06 (3.31%) Live

$GRCE 8-K SEC Filings

Filed On Filing
12 Nov 2026 8-K: Results of Operations and Financial Condition

Princeton, N.J., November 12, 2026 (GLOBE NEWSWIRE) — Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage biopharma company advancing GTx-104, a novel, injectable formulation of nimodipine that has c...

18 Sep 2026 8-K: Submission of Matters to a Vote of Security Holders

On September 17, 2026, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended,...

13 Aug 2026 8-K: Results of Operations and Financial Condition

Princeton, NJ, August 13, 2026 (GLOBE NEWSWIRE)—Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine...

06 Aug 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +1 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of August 4, 2026, by and among Grace Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (...

28 Jul 2026 8-K: Other Events

Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of...

18 Jun 2026 8-K: Other Events

Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of...

18 Jun 2026 8-K: Results of Operations and Financial Condition

Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission

05 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

This Consulting Agreement (“Agreement”) is effective as of June 5, 2026 (the “Effective Date”) by and between Grace Therapeutics, Inc., a Delaware corporation, with a business address of 103 Carnegie Center, Suite 300, Princeton, NJ 0854...

27 Apr 2026 8-K: Other Events

Summary 2 Forward Looking Statements Statements in this presentation that are not statements of historical or current fact constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of...

23 Apr 2026 8-K: Other Events

FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information

12 Feb 2026 8-K: Results of Operations and Financial Condition

FDA Established April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)

12 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

This letter serves to modify and amend the Letter Agreement (“Letter Agreement”) dated as of November 12, 2025, between you and Grace Therapeutics, Inc. (“Company”) containing the terms and conditions of your employment as Vice President...

13 Nov 2025 8-K: Results of Operations and Financial Condition; Other Events

Announced U.S. Food and Drug Administration (FDA) Acceptance for Review

23 Oct 2025 8-K: Other Events

Grace Therapeutics Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review

18 Sep 2025 8-K: Other Events

Grant of First Method of Use Patent Adds New Pillar to Grace’s Multi-layered Intellectual Property and Potential Market Exclusivity Protection

12 Sep 2025 8-K: Submission of Matters to a Vote of Security Holders

On September 12, 2025, Grace Therapeutics, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”). Proxies for the Meeting were solicited pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended,...

27 Aug 2025 8-K: Other Events

FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)

12 Aug 2025 8-K: Results of Operations and Financial Condition

Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for GTx-104 Seeking Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)

25 Jun 2025 8-K: Other Events

Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)

23 Jun 2025 8-K: Results of Operations and Financial Condition

Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support